Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
出版年份 2012 全文链接
标题
Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
作者
关键词
-
出版物
Human Vaccines & Immunotherapeutics
Volume 8, Issue 7, Pages 866-872
出版商
Informa UK Limited
发表日期
2012-06-28
DOI
10.4161/hv.20229
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Seroprevalence of Serum Bactericidal Antibodies against Group W135 and Y Meningococci in England in 2009
- (2011) Caroline L. Trotter et al. Clinical and Vaccine Immunology
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents
- (2011) Christopher J. Gill et al. Human vaccines & immunotherapeutics
- Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults
- (2011) Nancy Bermal et al. Human vaccines & immunotherapeutics
- Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile
- (2011) Ziad A. Memish et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
- (2011) Roger Baxter et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children
- (2011) Markus Knuf et al. VACCINE
- Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial
- (2011) Timo Vesikari et al. VACCINE
- Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
- (2010) H. Campbell et al. Clinical and Vaccine Immunology
- Meningococcal carriage by age: a systematic review and meta-analysis
- (2010) Hannah Christensen et al. LANCET INFECTIOUS DISEASES
- Quadrivalent meningococcal vaccines: Hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine
- (2010) Michael Bröker et al. Travel Medicine and Infectious Disease
- Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine
- (2009) R. Borrow et al. Clinical and Vaccine Immunology
- Global epidemiology of meningococcal disease
- (2009) Lee H. Harrison et al. VACCINE
- A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
- (2009) M. Knuf et al. VACCINE
- Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era
- (2008) C. L. Trotter et al. Clinical and Vaccine Immunology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started